Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2024-11-05 Call Transcript
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is an invitation and announcement for an earnings conference call to discuss the operational and financial performance for the half-year period H1 FY25. It includes details about the call timing, speakers, dial-in numbers, and registration instructions. There are no actual financial statements or substantive financial data presented in the text. The document is not the earnings release itself but a notice about the upcoming earnings call. According to the classification rules, such a document is best classified as a Call Transcript (CT) if it contained the full transcript, but since this is only an invitation and announcement, it does not qualify as a transcript. It is also not a report publication announcement (RPA) because it does not mention a report being attached or published. The best fitting category is Call Transcript (CT) as it relates to the earnings call event, even though it is an invitation rather than the transcript itself, it is the closest match among the options provided. Confidence is high given the clear context and regulatory references to the earnings call.
2024-11-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings conference call to discuss the operational and financial performance for the first half of fiscal year 2025 (H1 FY25). It references a scheduled event rather than providing actual financial results or detailed analysis. The document is short (922 characters) and serves as an announcement of the call, not the call transcript itself or the financial report. Therefore, it fits best under the category of Call Transcript (CT) as it relates to an earnings call, but since it is only an announcement of the call, it is not the transcript itself. However, the closest specific category for an announcement of an earnings call is still Call Transcript (CT) because it pertains directly to the earnings call event. Confidence is high due to clear mention of earnings call and regulatory reference to SEBI listing obligations.
2024-11-04 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-02 English
Corrigendum
Regulatory Filings Classification · 95% confidence The document is a corrigendum to the notice of an Extra Ordinary General Meeting (EGM) scheduled for November 12, 2024. It amends and provides additional details to the explanatory statement of the EGM notice, specifically related to a preferential issue of equity shares. The document references the original EGM notice dated October 19, 2024, and clarifies points in the explanatory statement. It is an announcement related to the EGM notice, not the EGM notice itself or the voting results. The document is not a full report but a supplementary notice to shareholders about changes to the EGM notice. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) less well than a corrigendum to a meeting notice. Since it is a corrigendum to the EGM notice, it is best classified under Regulatory Filings (RNS) as it is a regulatory announcement and does not contain voting results or the meeting materials themselves. The document length (9159 characters) and content confirm it is a detailed regulatory announcement rather than a full report or presentation.
2024-10-28 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement from Beta Drugs Limited addressed to the National Stock Exchange of India. It highlights the company receiving the Forbes Asia 'Best Under a Billion' 2024 award for the third consecutive year and discusses the company's global expansion and regulatory compliance achievements. There are no financial statements, detailed financial data, or comprehensive report content. The document is under 5,000 characters and serves as a news or recognition announcement rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings as it lacks regulatory or compliance content. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-10-28 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to the National Stock Exchange of India Limited regarding a newspaper advertisement for an Extra Ordinary General Meeting (EGM) scheduled on 12th November 2024. It includes details about the publication of the notice in newspapers and is intended for information and record purposes. The content does not contain any financial statements, management discussion, audit information, or detailed report data. Instead, it is an announcement about the notice publication for the EGM. Therefore, this document fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like AGM Information or Proxy Solicitation. The document length is 15,000 characters, but the content is primarily an announcement rather than a report or detailed filing.
2024-10-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.